1
|
Nascimento SMRD, Ferry A, Gallier F, Lubin-Germain N, Uziel J, Gonzales S, Miranda LSDME. Developments in the chemistry and biology of 1,2,3-triazolyl-C-nucleosides. Arch Pharm (Weinheim) 2024; 357:e2300580. [PMID: 38150650 DOI: 10.1002/ardp.202300580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2023] [Revised: 11/28/2023] [Accepted: 11/30/2023] [Indexed: 12/29/2023]
Abstract
In the last 50 years, nucleoside analogs have been introduced to drug therapy as antivirals for different types of cancer due to their interference in cellular proliferation. Among the first line of nucleoside treatment drugs, ribavirin (RBV) is a synthetic N-nucleoside with a 1,2,4-triazole moiety that acts as a broad-spectrum antiviral. It is on the World Health Organization (WHO) list of essential medicines. However, this important drug therapy causes several side effects due to its nonspecific mechanism of action. There is thus a need for a continuous study of its scaffold. A particular approach consists of connecting d-ribose to the nitrogen-containing base with a C-C bond. It provides more stability against enzymatic action and a better pharmacologic profile. The coronavirus disease (COVID) pandemic has increased the need for more solutions for the treatment of viral infections. Among these solutions, remdesivir, the first C-nucleoside, has been approved by the Food and Drug Administration (FDA) for clinical use against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It drew attention to the study of the C-nucleoside scaffold. Different C-nucleoside patterns have been synthesized over the years. They show many important activities against viruses and cancer cell lines. 1,2,3-Triazolyl-C-nucleoside derivatives are a prolific and efficient subclass of RBV analogs close to the already-known RBV with a C-C bond modification. These compounds are often prepared by alkynylation of the d-ribose ring followed by azide-alkyne cycloaddition. They are reported to be active against the Crimean-Congo hemorrhagic fever virus and several tumoral cell lines, showing promising biological potential. In this review, we explore such approaches to 1,2,3-triazolyl-C-nucleosides and their evolution over the years.
Collapse
Affiliation(s)
| | - Angélique Ferry
- CY Cergy Paris Université, CNRS, BioCIS, Cergy-Pontoise, France
- Université Paris-Saclay, CNRS, BioCIS, Châtenay-Malabry, France
| | - Florian Gallier
- CY Cergy Paris Université, CNRS, BioCIS, Cergy-Pontoise, France
- Université Paris-Saclay, CNRS, BioCIS, Châtenay-Malabry, France
| | - Nadège Lubin-Germain
- CY Cergy Paris Université, CNRS, BioCIS, Cergy-Pontoise, France
- Université Paris-Saclay, CNRS, BioCIS, Châtenay-Malabry, France
| | - Jacques Uziel
- CY Cergy Paris Université, CNRS, BioCIS, Cergy-Pontoise, France
- Université Paris-Saclay, CNRS, BioCIS, Châtenay-Malabry, France
| | - Simon Gonzales
- CY Cergy Paris Université, CNRS, BioCIS, Cergy-Pontoise, France
- Université Paris-Saclay, CNRS, BioCIS, Châtenay-Malabry, France
| | | |
Collapse
|
2
|
da Silva EF, Antunes Fernandes KH, Diedrich D, Gotardi J, Freire Franco MS, Tomich de Paula da Silva CH, Duarte de Souza AP, Baggio Gnoatto SC. New triazole-substituted triterpene derivatives exhibiting anti-RSV activity: synthesis, biological evaluation, and molecular modeling. Beilstein J Org Chem 2022; 18:1524-1531. [PMID: 36447520 PMCID: PMC9663970 DOI: 10.3762/bjoc.18.161] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2022] [Accepted: 10/31/2022] [Indexed: 09/28/2023] Open
Abstract
Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory tract infections in infants. Currently, ribavirin, a nucleoside analog containing a 1,2,4-triazole-3-carboxamide moiety, is a first-line drug for its treatment, however, its clinical use has been limited due to its side effects. Here, we designed two new nitroaryl-1,2,3-triazole triterpene derivatives as novel anti-RSV drugs. Their anti-RSV and cytotoxic activity were evaluated in vitro, RSV protein F gene effects by RT-PCR and molecular modeling with inosine monophosphate dehydrogenase (IMPDH) were performed. Compound 8 was the best performing compound, with an EC50 value of 0.053 μM, a TI of 11160.37 and it inhibited hRSV protein F gene expression by approximately 65%. Molecular docking showed a top-ranked solution located in the same region occupied by crystallographic ligands in their complex with IMPDH. The results obtained in this study suggest that compound 8 might be a new anti-RSV candidate.
Collapse
Affiliation(s)
- Elenilson F da Silva
- Phytochemistry and Organic Synthesis Laboratory, School of Pharmacy, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
| | - Krist Helen Antunes Fernandes
- Clinical and Immunology Laboratory, Biomedical Research Institute, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil
| | - Denise Diedrich
- Phytochemistry and Organic Synthesis Laboratory, School of Pharmacy, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
| | - Jessica Gotardi
- Phytochemistry and Organic Synthesis Laboratory, School of Pharmacy, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
| | - Marcia Silvana Freire Franco
- Laboratory of Computational Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP 14040-020, Brazil
| | - Carlos Henrique Tomich de Paula da Silva
- Laboratory of Computational Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP 14040-020, Brazil
| | - Ana Paula Duarte de Souza
- Clinical and Immunology Laboratory, Biomedical Research Institute, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil
| | - Simone Cristina Baggio Gnoatto
- Phytochemistry and Organic Synthesis Laboratory, School of Pharmacy, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
| |
Collapse
|
3
|
Bozinovic N, Aguiar VMD, Ferry A, Gallier F, Lubin-Germain N, Uziel J, Miranda LSDME. Studies on the synthesis of 1'-CN-triazolyl- C-ribosides. Org Biomol Chem 2022; 20:7261-7269. [PMID: 36069280 DOI: 10.1039/d2ob01403c] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The search for broad-spectrum antiviral compounds is a continuous mandatory effort. The recent approval of the first C-nucleoside carrying a nitrile as a substituent at the C1' position of the ribose ring has raised interest in this underexplored substitution pattern. We have previously reported the development of different 1,2,3-triazolyl-C-ribonucleosides with anticancer and antiviral activities. Herein we report our results on the incorporation of a C1'-CN group in 1,2,3-triazolyl-C-ribonucleosides.
Collapse
Affiliation(s)
- Nina Bozinovic
- CY Cergy Paris Université, CNRS, BioCIS, 95000, Cergy-Pontoise, France
| | - Viviane Marques de Aguiar
- Biocatalysis and Organic Synthesis Group, Universidade Federal do Rio de Janeiro, Av Athos da Silveira Ramos 149, Centro de Tecnologia, Bl A, 21941909 Ilha do Fundão, Rio de Janeiro, Brazil.
| | - Angélique Ferry
- CY Cergy Paris Université, CNRS, BioCIS, 95000, Cergy-Pontoise, France
| | - Florian Gallier
- CY Cergy Paris Université, CNRS, BioCIS, 95000, Cergy-Pontoise, France
| | | | - Jacques Uziel
- CY Cergy Paris Université, CNRS, BioCIS, 95000, Cergy-Pontoise, France
| | - Leandro Soter de Mariz E Miranda
- CY Cergy Paris Université, CNRS, BioCIS, 95000, Cergy-Pontoise, France.,Biocatalysis and Organic Synthesis Group, Universidade Federal do Rio de Janeiro, Av Athos da Silveira Ramos 149, Centro de Tecnologia, Bl A, 21941909 Ilha do Fundão, Rio de Janeiro, Brazil.
| |
Collapse
|
4
|
Gonzalez S, Brzuska G, Ouarti A, Gallier F, Solarte C, Ferry A, Uziel J, Krol E, Lubin-Germain N. Anti-HCV and Zika activities of ribavirin C-nucleosides analogues. Bioorg Med Chem 2022; 68:116858. [PMID: 35661850 DOI: 10.1016/j.bmc.2022.116858] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2022] [Revised: 05/23/2022] [Accepted: 05/25/2022] [Indexed: 11/27/2022]
Abstract
Ribavirin is an unnatural nucleoside exhibiting broad spectrum of antiviral and antitumor activities, still very widely studied particularly in a repositioning approach. C-triazolyl nucleoside analogues of ribavirin have been synthesized, as well as prodrugs and glycosylated or peptide conjugates to allow a better activity by vectorization into the liver or by facilitating uptake into the cells. The antiviral properties of all synthesized compounds have been evaluated in vitro against two important human viral pathogens belonging to the Flaviviridae family: hepatitis C virus (HCV) and Zika virus (ZIKV). There are no therapeutic options for Zika virus, whereas those available for HCV can be still improved. Our results indicated that compound 2 carrying an N-hydroxy carboxamide function exhibits the most inhibitory activities against both viruses. This compound moderately inhibited the propagation of HCV with an IC50 value of 49.1 μM and Zika virus with an IC50 of 33.2 μM comparable to ribavirin in the Vero cell line. The results suggest that compound 2 and its new derivatives may be candidates for further development of new anti-HCV and anti-ZIKV antiviral drugs.
Collapse
Affiliation(s)
- Simon Gonzalez
- CY Cergy Paris Université, CNRS, BioCIS, 95000 Cergy Pontoise, France; Université Paris-Saclay, CNRS, BioCIS, 92290 Châtenay-Malabry, France
| | - Gabriela Brzuska
- Department of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Abrahama 58, 80-307 Gdansk, Poland
| | - Abdelhakim Ouarti
- CY Cergy Paris Université, CNRS, BioCIS, 95000 Cergy Pontoise, France; Université Paris-Saclay, CNRS, BioCIS, 92290 Châtenay-Malabry, France
| | - Florian Gallier
- CY Cergy Paris Université, CNRS, BioCIS, 95000 Cergy Pontoise, France; Université Paris-Saclay, CNRS, BioCIS, 92290 Châtenay-Malabry, France
| | - Carmen Solarte
- CY Cergy Paris Université, CNRS, BioCIS, 95000 Cergy Pontoise, France; Université Paris-Saclay, CNRS, BioCIS, 92290 Châtenay-Malabry, France
| | - Angélique Ferry
- CY Cergy Paris Université, CNRS, BioCIS, 95000 Cergy Pontoise, France; Université Paris-Saclay, CNRS, BioCIS, 92290 Châtenay-Malabry, France
| | - Jacques Uziel
- CY Cergy Paris Université, CNRS, BioCIS, 95000 Cergy Pontoise, France; Université Paris-Saclay, CNRS, BioCIS, 92290 Châtenay-Malabry, France
| | - Ewelina Krol
- Department of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Abrahama 58, 80-307 Gdansk, Poland.
| | - Nadège Lubin-Germain
- CY Cergy Paris Université, CNRS, BioCIS, 95000 Cergy Pontoise, France; Université Paris-Saclay, CNRS, BioCIS, 92290 Châtenay-Malabry, France.
| |
Collapse
|
5
|
Takada H, Takizawa N, Shibasaki S, Asaba H, Igarashi M, Shibasaki M, Takahashi Y. Synthesis and antiviral activity of formycin derivatives with anti-influenza virus activity. Bioorg Med Chem 2022; 57:116613. [DOI: 10.1016/j.bmc.2022.116613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2021] [Revised: 01/05/2022] [Accepted: 01/05/2022] [Indexed: 11/02/2022]
|
6
|
Sabat N, Migianu-Griffoni E, Tudela T, Lecouvey M, Kellouche S, Carreiras F, Gallier F, Uziel J, Lubin-Germain N. Synthesis and antitumor activities investigation of a C-nucleoside analogue of ribavirin. Eur J Med Chem 2019; 188:112009. [PMID: 31883488 DOI: 10.1016/j.ejmech.2019.112009] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2019] [Revised: 12/09/2019] [Accepted: 12/21/2019] [Indexed: 02/05/2023]
Abstract
SRO-91 is a non-natural ribofuranosyl-1,2,3-triazole C-nucleoside obtained by a synthetic sequence involving a C-alkynyl glycosylation mediated by metallic indium and a Huisgen cycloaddition for the construction of the triazole. Its structure is close to the one of ribavirin, a drug presenting a broad-spectrum against viral infections. SRO-91 antitumor activities were investigated on 9 strains of tumor cells and IC50 of the order of 1 μM were obtained on A431 epidermoid carcinoma cells and B16F10 skin melanoma cells. In addition, studies of ovarian tumor cell inhibitions show an interesting activity in regard to the need for new drugs for this pathology. Finally, cytotoxicity and mouse toxicity studies reveal a favorable therapeutic index for SRO-91.
Collapse
Affiliation(s)
- Nazarii Sabat
- Laboratoire de Chimie Biologique, University of Cergy-Pontoise, 5 mail Gay-Lussac, 95031, Cergy-Pontoise, France
| | - Evelyne Migianu-Griffoni
- Université; Paris 13, Sorbonne Paris Cité, Laboratoire de Chimie, Structure, Propriétés de Biomatériaux et d'Agents Thérapeutiques (CSPBAT), CNRS UMR 7244, 74, rue Marcel, Cachin, F-93017, Bobigny, France
| | - Tiffany Tudela
- Equipe de Recherche sur les Relations Matrice Extracellulaire-Cellules, ERRMECe (EA1391), Institut des Matériaux, I-MAT (FD4122), University of Cergy-Pontoise, MIR, rue Descartes, 95031, Neuville sur Oise Cedex, France
| | - Marc Lecouvey
- Université; Paris 13, Sorbonne Paris Cité, Laboratoire de Chimie, Structure, Propriétés de Biomatériaux et d'Agents Thérapeutiques (CSPBAT), CNRS UMR 7244, 74, rue Marcel, Cachin, F-93017, Bobigny, France
| | - Sabrina Kellouche
- Equipe de Recherche sur les Relations Matrice Extracellulaire-Cellules, ERRMECe (EA1391), Institut des Matériaux, I-MAT (FD4122), University of Cergy-Pontoise, MIR, rue Descartes, 95031, Neuville sur Oise Cedex, France
| | - Franck Carreiras
- Equipe de Recherche sur les Relations Matrice Extracellulaire-Cellules, ERRMECe (EA1391), Institut des Matériaux, I-MAT (FD4122), University of Cergy-Pontoise, MIR, rue Descartes, 95031, Neuville sur Oise Cedex, France
| | - Florian Gallier
- Laboratoire de Chimie Biologique, University of Cergy-Pontoise, 5 mail Gay-Lussac, 95031, Cergy-Pontoise, France
| | - Jacques Uziel
- Laboratoire de Chimie Biologique, University of Cergy-Pontoise, 5 mail Gay-Lussac, 95031, Cergy-Pontoise, France
| | - Nadège Lubin-Germain
- Laboratoire de Chimie Biologique, University of Cergy-Pontoise, 5 mail Gay-Lussac, 95031, Cergy-Pontoise, France.
| |
Collapse
|
7
|
Wambecke A, Laurent-Issartel C, Leroy-Dudal J, Giffard F, Cosson F, Lubin-Germain N, Uziel J, Kellouche S, Carreiras F. Evaluation of the potential of a new ribavirin analog impairing the dissemination of ovarian cancer cells. PLoS One 2019; 14:e0225860. [PMID: 31825993 PMCID: PMC6905583 DOI: 10.1371/journal.pone.0225860] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2019] [Accepted: 11/13/2019] [Indexed: 12/12/2022] Open
Abstract
Epithelial ovarian cancers are insidious pathologies that give a poor prognosis due to their late discovery and the increasing emergence of chemoresistance. Development of small pharmacological anticancer molecules remains a major challenge. Ribavirin, usually used in the treatment of hepatitis C virus infections and more recently few cancers, has been a suggestion. However, Ribavirin has many side-effects, suggesting that the synthesis of analogs might be more appropriate. We have investigated the effect of a Ribavirin analog, SRO-91, on cancer cell behavioral characteristics considered as some of the hallmarks of cancer. Two human ovarian adenocarcinoma cell lines (SKOV3 and IGROV1) and normal cells (mesothelial and fibroblasts) have been used to compare the effects of SRO-91 with those of Ribavirin on cell behavior underlying tumor cell dissemination. SRO-91, like Ribavirin, inhibits proliferation, migration, clonogenicity and spheroids formation of cancer cells. Unlike Ribavirin, SRO-91 is preferentially toxic to cancer compared with normal cells. An in vitro physiologically relevant model showed that SRO-91, like Ribavirin or cisplatin, inhibits cancer cell implantation onto peritoneal mesothelium. In conclusion, SRO-91 analog effects on tumor dissemination and its safety regarding non-cancerous (normal) cells are encouraging findings a promising drug for the treatment of ovarian cancer.
Collapse
Affiliation(s)
- Anaïs Wambecke
- Equipe de Recherche sur les Relations Matrice Extracellulaire-Cellules, ERRMECe (EA1391), Institut des Matériaux, I-MAT (FD4122), University of Cergy-Pontoise, MIR, rue Descartes, France
- Normandie University, UNICAEN, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment, BioTICLA Axis (Biology and Innovative Therapeutics for Ovarian Cancers), Esplanade de la Paix, Caen, France
| | - Carine Laurent-Issartel
- Equipe de Recherche sur les Relations Matrice Extracellulaire-Cellules, ERRMECe (EA1391), Institut des Matériaux, I-MAT (FD4122), University of Cergy-Pontoise, MIR, rue Descartes, France
| | - Johanne Leroy-Dudal
- Equipe de Recherche sur les Relations Matrice Extracellulaire-Cellules, ERRMECe (EA1391), Institut des Matériaux, I-MAT (FD4122), University of Cergy-Pontoise, MIR, rue Descartes, France
| | - Florence Giffard
- Normandie University, UNICAEN, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment, BioTICLA Axis (Biology and Innovative Therapeutics for Ovarian Cancers), Esplanade de la Paix, Caen, France
| | - Fanny Cosson
- Laboratoire de Chimie Biologique, University of Cergy-Pontoise, mail Gay-Lussac, Cergy-pontoise, France
| | - Nadège Lubin-Germain
- Laboratoire de Chimie Biologique, University of Cergy-Pontoise, mail Gay-Lussac, Cergy-pontoise, France
| | - Jacques Uziel
- Laboratoire de Chimie Biologique, University of Cergy-Pontoise, mail Gay-Lussac, Cergy-pontoise, France
| | - Sabrina Kellouche
- Equipe de Recherche sur les Relations Matrice Extracellulaire-Cellules, ERRMECe (EA1391), Institut des Matériaux, I-MAT (FD4122), University of Cergy-Pontoise, MIR, rue Descartes, France
| | - Franck Carreiras
- Equipe de Recherche sur les Relations Matrice Extracellulaire-Cellules, ERRMECe (EA1391), Institut des Matériaux, I-MAT (FD4122), University of Cergy-Pontoise, MIR, rue Descartes, France
| |
Collapse
|